Corcept Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue grew 4.9% year-over-year to $164.9M, but net loss reached $31.8M due to launch costs. Lifyorli’s early FDA approval and rapid adoption, plus strong endocrinology growth, led to raised 2026 guidance of $950M–$1.05B.
Fiscal Year 2025
-
Revenue grew 13% to $761M in 2025, driven by record Cushing's syndrome demand, while net income declined. Regulatory and legal setbacks impacted relacorilant, but strong clinical data and pharmacy transition support future growth.
-
Q3 2025 revenue rose 13.8% year-over-year to $207.6M, but net income fell to $19.7M. Strong hypercortisolism growth and expanded pipeline drive optimism, with Relacorilant FDA approvals expected in late 2025 and mid-2026. Guidance raised to $800–$850M for 2025.
-
Q2 2025 revenue rose 19% year-over-year to $194.4 million, driven by record prescription growth and expanding market awareness. Relacorilant is expected to replace Korlym and drive multi-billion dollar annual sales, with key regulatory decisions and expanded pharmacy capacity anticipated by year-end.
-
Q1 2025 revenue grew 7% year-over-year to $157.2M, with strong patient and prescriber growth in hypercortisolism. Relacorilant's NDA is under FDA review, and oncology results support expansion. 2025 revenue guidance remains $900M–$950M.
Fiscal Year 2024
-
2024 saw 40% revenue growth and record Korlym adoption, with strong cash reserves and a positive outlook. NDA for relacorilant is under FDA review, pivotal ROSELLA results are imminent, and the addressable market is expanding rapidly.
-
Q3 2024 revenue grew 48% year-over-year to $182.5 million, with net income at $47.2 million and cash of $547.6 million. Raised 2024 revenue guidance to $675–$700 million, driven by strong Korlym performance and positive relacorilant phase III results supporting an NDA submission.
-
Q2 2024 revenue grew 39% year-over-year to $163.8 million, with net income rising to $35.5 million. Raised 2024 revenue guidance to $640–$670 million, driven by strong commercial performance and clinical milestones, including positive GRACE trial results and expanded market awareness.